N-(6-benzylamino-4-o-tolyl-pyridin-3-yl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(6-benzylamino-4-o-tolyl-pyridin-3-yl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
• 英文别名: N-[6-(benzylamino)-4-(2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide
• 化学式: C₃₂H₂₉F₆N₃O
• 分子量: 585.6
• InChiKey: ISQNRJVINJDUKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  42
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  N-(6-benzylamino-4-o-tolyl-pyridin-3-yl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide 、 、 盐酸 在 钯 乙酸乙酯 、 碳酸氢钠 、 magnesium sulfate 作用下， 以 乙醇 、 甲醇 为溶剂， 25.0 ℃ 、133.32 MPa 条件下， 反应 20.0h， 以afforded 514 mg (81%) of the title compound as light brown crystals的产率得到N-(6-amino-4-o-tolyl-pyridin-3-yl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  参考文献：
  名称：

  4-phenyl-pyridine derivatives

  摘要：

  该相关发明的化合物是由一种含有氧或氮的桥连接到苯基衍生物的4-苯基吡啶衍生物组成。

  公开号：

  US06297375B1
• 作为产物：
  描述：

  benzyl-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-carbamic acid benzyl ester 在 钯 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、13.33 MPa 条件下， 反应 1.0h， 以afforded 795 mg (quantitative) of the title compound as a yellow oil的产率得到N-(6-benzylamino-4-o-tolyl-pyridin-3-yl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
  参考文献：
  名称：

  Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors

  摘要：

  本发明涉及一种杂环芳基取代酰胺，其具有神经激肽1（NK-1，物质P）受体的拮抗活性。

  公开号：

  US06624176B2

文献信息

• Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors
  申请人：——

  公开号：US20020038030A1

  公开（公告）日：2002-03-28

  The present invention is a heteroaromatic substituted amide showing antagonist activity to neurokinin 1 (NK-1, substance P) receptors.

  这项发明是一种杂环芳基取代酰胺，显示对神经激肽1（NK-1，物质P）受体的拮抗活性。
• 4-phenyl-pyridine derivatives
  申请人：——

  公开号：US20020091265A1

  公开（公告）日：2002-07-11

  The present invention relates to compounds of the general formula 1 R is lower alkyl, lower alkoxy, halogen or trifluoromethyl; R 1 is halogen or hydrogen; and when p is 1, R 1 in addition to the above substituents may be taken together with R 1 to form —CH═CH—CH═CH—, R 2 and R 2′ are independently hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; and when n is 1, R 2 and R 2′ may in addition to the above substituents form —CH═CH—CH═CH—, unsubstituted or substituted by one or two substituents selected from lower alkyl or lower alkoxy; R 3 and R 3′ are hydrogen, lower alkyl or taken together with the attached carbon atom form a cycloalkyl group; R 4 is hydrogen, —N(R 5 ) 2 , —N(R 5 )(CH 2 ) n OH, —N(R 5 )S(O) 2 -lower alkyl, N(R 5 )S(O) 2 -phenyl, —N═CH—N(R 5 ) 2 , —N(R 5 )C(O)R 5 ; 2 3 R 5 is hydrogen, C 3-6 -cycloalkyl, benzyl or lower alkyl; R 6 is hydroxy, lower alkyl; —(CH 2 ) n COO—(R 5 ), —N(R 5 )CO-lower alkyl, hydroxy-lower alkyl;—(CH 2 ) q CN; —(CH 2 ) n O(CH 2 ) n OH, —CHO or a 5-or 6 membered heterocyclic ring containing from 1 to 4 heteroatoms, selected from the group consisting of oxygen, nitrogen, and sulfur, and with one of the carbon atoms in said ring being unsubstituted or substituted with an oxo group, which heterocyclic ring is directly bonded or bonded via an alkylene group, to the remainder of the molecule; 4 is a cyclic tertiary amine which may contain one additional heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur wherein any sulfur present in the ring is thio or can be oxidized to sulfoxide or sulfur dioxide, by which said cyclic tertiary amine is directly attached to the remainder of the molecule or is attached through the linker —(CH 2 ) n N(R 5 )—; X is —C(O)N(R 5 )—, —(CH 2 ) m O—, —(CH 2 ) m N(R 5 )—, —N(R 5 )C(O)—, or —N(R 5 )(CH 2 ) m —; n, p and q are 1 to 4; and m is 1 or2; and to pharmaceutically acceptable acid addition salts thereof The compounds of this invention show a high affinity to the NK-1 receptor. They may be used for the treatment of diseases relating to NK1 antagonists.

  本发明涉及一般式的化合物1 其中，R为较低的烷基，较低的烷氧基，卤素或三氟甲基；R1为卤素或氢；当p为1时，除了上述取代基外，R1还可以与R1一起形成—CH═CH—CH═CH—；R2和R2'独立地为氢，卤素，三氟甲基，较低的烷氧基或氰基；当n为1时，除了上述取代基外，R2和R2'还可以形成—CH═CH—CH═CH—，未取代或被选自较低烷基或较低烷氧基的一到两个取代基取代；R3和R3'为氢，较低的烷基或与附加的碳原子一起形成环烷基；R4为氢，—N(R5)2，—N(R5)(CH2)nOH，—N(R5)S(O)2-较低烷基，N(R5)S(O)2-苯基，—N═CH—N(R5)2，—N(R5)C(O)R5；R5为氢，C3-6环烷基，苄基或较低的烷基；R6为羟基，较低的烷基；—(CH2)nCOO—(R5)，—N(R5)CO-较低烷基，羟基-较低烷基；—(CH2)qCN；—(CH2)nO(CH2)nOH，—CHO或含有1至4个异原子的5或6元杂环，所述异原子选自氧，氮和硫，所述环中的一个碳原子未取代或被氧代基取代，该杂环通过烷基链直接键合或键合到分子的其余部分上；4为一个环状的三级胺，该胺可以包含一个额外的异原子，所述异原子选自氧，氮和硫，环中存在的任何硫为硫或可被氧化为亚硫酸盐或二氧化硫，该环状三级胺直接附着于分子的其余部分或通过连接剂—(CH2)nN(R5)—附着；X为—C(O)N(R5)—，—(CH2)mO—，—(CH2)mN(R5)—，—N(R5)C(O)—或—N(R5)(CH2)m—；n，p和q为1至4；m为1或2；以及其药学上可接受的酸盐。本发明的化合物表现出对NK-1受体的高亲和力。它们可用于治疗与NK1拮抗剂相关的疾病。
• 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1035115B1

  公开（公告）日：2004-09-29
• 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1305319A1

  公开（公告）日：2003-05-02
• US6297375B1
  申请人：——

  公开号：US6297375B1

  公开（公告）日：2001-10-02